| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 21/02/2018 | 12:57 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 05/02/2018 | 23:05 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 18/01/2018 | 23:11 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 18/01/2018 | 22:59 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 18/01/2018 | 20:05 | Edgar (US Regulatory) | Statement of Beneficial Ownership (sc 13d) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 17/01/2018 | 22:10 | PR Newswire (US) | Evofem Announces Closing Of Merger With Neothetics | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 05/01/2018 | 23:19 | Edgar (US Regulatory) | Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 05/01/2018 | 23:15 | GlobeNewswire Inc. | Neothetics Announces Adjournment of Special Stockholders Meeting to Solicit Additional Votes for Merger With Evofem | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 13/12/2017 | 12:01 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 12/12/2017 | 22:23 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 07/12/2017 | 23:11 | Edgar (US Regulatory) | Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 28/11/2017 | 17:28 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 08/11/2017 | 14:03 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 08/11/2017 | 14:00 | GlobeNewswire Inc. | Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 31/10/2017 | 22:11 | Edgar (US Regulatory) | Amended Current Report Filing (8-k/a) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 17/10/2017 | 14:00 | GlobeNewswire Inc. | Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 10/08/2017 | 14:00 | GlobeNewswire Inc. | Neothetics Provides Business Update and Reports Second Quarter 2017 Financial Results | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 10/07/2017 | 23:45 | GlobeNewswire Inc. | Neothetics Announces Review of Strategic Alternatives | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 26/06/2017 | 14:00 | GlobeNewswire Inc. | Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutane... | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 11/05/2017 | 14:00 | GlobeNewswire Inc. | Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 04/05/2017 | 14:00 | GlobeNewswire Inc. | Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017 | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 28/04/2017 | 14:03 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 05/04/2017 | 14:00 | GlobeNewswire Inc. | Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 29/03/2017 | 14:00 | GlobeNewswire Inc. | Neothetics to Present at the 16th Annual Needham Healthcare Conference | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 23/03/2017 | 13:08 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 23/03/2017 | 13:00 | GlobeNewswire Inc. | Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 20/03/2017 | 13:00 | GlobeNewswire Inc. | Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subc... | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 16/03/2017 | 13:00 | GlobeNewswire Inc. | Neothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017 | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 23/12/2016 | 14:00 | GlobeNewswire Inc. | Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat | NASDAQ:NEOT | Neothetics, Inc. (delisted) |
| 10/11/2016 | 14:00 | GlobeNewswire Inc. | Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results | NASDAQ:NEOT | Neothetics, Inc. (delisted) |